Skip to main content
. 2016 Dec 3;8(5):7559–7571. doi: 10.18632/oncotarget.13791

Figure 2. The effects of etanercept and adalimumab on IL-17A, IL-17F and IL-22 production in Th17-polarized cells from patients with RA.

Figure 2

The levels of Th17-related cytokines, including (A) IL-17A, (B) IL-17F and (C) IL-22, in the supernatants of Th17-polarized cells from four healthy donors (HD) and six patients with RA that were pretreated in vitro with or without etanercept (1 μg/ml) or adalimumab (1 or 10 μg/ml) were determined by ELISA. Horizontal bars indicate the median. *P < 0.05, **P < 0.01 and ***P < 0.001.